CA2073601A1 - Composition pharmaceutique contenant de la rifaximine pour le traitement des infections vaginales - Google Patents

Composition pharmaceutique contenant de la rifaximine pour le traitement des infections vaginales

Info

Publication number
CA2073601A1
CA2073601A1 CA2073601A CA2073601A CA2073601A1 CA 2073601 A1 CA2073601 A1 CA 2073601A1 CA 2073601 A CA2073601 A CA 2073601A CA 2073601 A CA2073601 A CA 2073601A CA 2073601 A1 CA2073601 A1 CA 2073601A1
Authority
CA
Canada
Prior art keywords
treatment
pharmaceutical compositions
compositions containing
vaginal
vaginal infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2073601A
Other languages
English (en)
Other versions
CA2073601C (fr
Inventor
Egidio Marchi
Leone Gabrielle Rotini
Subhash Desai
Massimo Grilli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Wasserman SpA
Original Assignee
Alfa Wasserman SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wasserman SpA filed Critical Alfa Wasserman SpA
Publication of CA2073601A1 publication Critical patent/CA2073601A1/fr
Application granted granted Critical
Publication of CA2073601C publication Critical patent/CA2073601C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CA002073601A 1991-12-17 1992-07-10 Composition pharmaceutique contenant de la rifaximine pour le traitement des infections vaginales Expired - Lifetime CA2073601C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000476A/91 1991-12-17
ITBO910476A IT1253711B (it) 1991-12-17 1991-12-17 Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali

Publications (2)

Publication Number Publication Date
CA2073601A1 true CA2073601A1 (fr) 1993-06-18
CA2073601C CA2073601C (fr) 1996-07-09

Family

ID=11337881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002073601A Expired - Lifetime CA2073601C (fr) 1991-12-17 1992-07-10 Composition pharmaceutique contenant de la rifaximine pour le traitement des infections vaginales

Country Status (13)

Country Link
US (2) US5314904A (fr)
EP (1) EP0547294B1 (fr)
JP (1) JP2834951B2 (fr)
KR (1) KR0149519B1 (fr)
AT (1) ATE130510T1 (fr)
CA (1) CA2073601C (fr)
DE (1) DE69206245T2 (fr)
DK (1) DK0547294T3 (fr)
ES (1) ES2081531T3 (fr)
GR (1) GR3018205T3 (fr)
IT (1) IT1253711B (fr)
MX (1) MX9204132A (fr)
TW (1) TW217385B (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6462030B1 (en) * 1999-07-19 2002-10-08 New York Blood Center, Inc. Method for inactivating bacteria associated with bacterial vaginosis using cellulose acetate phthalate and/or hydroxypropyl methycellulose phthalate
US6251136B1 (en) * 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
ATE489937T1 (de) 2000-03-07 2010-12-15 Rush Presbyterian St Luke Zusammensetzungen und deren verwendung zum abfangen und inaktivieren pathogener mikroben und spermatozoen
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US6537538B2 (en) 2000-12-18 2003-03-25 Rush-Presbyterian-St. Luke's Medical Center Method for the prevention, inhibition, or treatment of vaginitis and/or bacterial vaginosis using polystyrene sulfonate
KR100392363B1 (ko) * 2000-12-26 2003-07-22 한국전자통신연구원 형광체 및 그 제조방법
CN1259049C (zh) * 2001-07-06 2006-06-14 苏坎波公司 包含白介素－2抑制剂和抗菌剂的局部给药组合物
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
AU2003279493B2 (en) 2002-10-25 2009-08-20 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
WO2004041240A1 (fr) * 2002-11-05 2004-05-21 Piero Chiarelli Delivrance continue et regulee de rifaximine et/ou d'autres substances
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
DK1635847T3 (da) * 2003-06-13 2019-10-28 Idh Holding Aps Behandling af symptomer forbundet med bakteriel vaginose
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
EP1667619A4 (fr) * 2003-09-19 2007-10-10 Drugtech Corp Systeme pharmaceutique d'administration
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
AU2004311879B2 (en) * 2003-12-31 2010-08-05 Cima Labs Inc. Effervescent oral opiate dosage form
US7858121B2 (en) * 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
WO2005065319A2 (fr) * 2003-12-31 2005-07-21 Cima Labs Inc. Forme galenique de fentanyl generalement lineaire effervescente et orale et ses procedes d'administration
US7125963B2 (en) * 2004-03-03 2006-10-24 En N Tech Inc Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
JP2008540508A (ja) * 2005-05-09 2008-11-20 フォーミックス エルティーディー． 起泡性ビヒクル及びその医薬組成物
AU2006244260A1 (en) * 2005-05-09 2006-11-16 Drugtech Corporation Modified-release pharmaceutical compositions
CA2635986A1 (fr) * 2006-01-05 2007-07-12 Drugtech Corporation Composition et methode d'utilisation de celle-ci
KR20080083190A (ko) * 2006-01-05 2008-09-16 드러그테크 코포레이션 외음질 표면에 생체접착을 위한 약물 전달 시스템
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080299182A1 (en) * 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
EP2837378A1 (fr) * 2007-07-06 2015-02-18 Lupin Limited Compositions pharmaceutiques de rifaximine
US8383151B2 (en) * 2007-07-06 2013-02-26 Lupin Limited Pharmaceutical compositions of rifaximin
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (fr) 2007-11-30 2009-06-04 Foamix Ltd. Peroxyde de benzoyle contenant de la mousse
WO2010041141A2 (fr) 2008-10-07 2010-04-15 Foamix Ltd. Support expansible à base d’huile et préparations
WO2009072007A2 (fr) 2007-12-07 2009-06-11 Foamix Ltd. Porteurs, formulations, procédés pour formuler des agents actifs instables pour application externe et utilisations associées
WO2009090558A2 (fr) 2008-01-14 2009-07-23 Foamix Ltd. Compositions pharmaceutiques pouvant mousser de poloxamère avec des agents actifs et/ou des cellules thérapeutiques, et utilisations
RU2011116400A (ru) 2008-09-26 2012-11-10 Аска Фармасьютикал Ко., Лтд. (Jp) Средство для предотвращения и/или лечения функционального расстройства желудочно-кишечного тракта
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013008A2 (fr) 2009-07-29 2011-02-03 Foamix Ltd. Compositions hydro-alcooliques moussantes à base d'agents non tensioactifs non polymères, mousses légères, et leurs utilisations
CA2769625C (fr) 2009-07-29 2017-04-11 Foamix Ltd. Compositions hydro-alcooliques moussantes non tensioactives, mousses legeres, et leurs utilisations
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
CN102686205A (zh) 2009-10-02 2012-09-19 弗艾米克斯有限公司 局部四环素组合物
JP6211768B2 (ja) * 2009-10-27 2017-10-11 ルピン・リミテッド リファキシミンの固溶体
WO2011061519A2 (fr) 2009-11-23 2011-05-26 Cipla Limited Composition de mousse topique
RU2012126080A (ru) * 2009-11-23 2013-12-27 Сипла Лимитед Местная пенообразующая композиция
US8445226B2 (en) 2010-02-01 2013-05-21 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
US7888062B1 (en) 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2012076832A1 (fr) 2010-12-09 2012-06-14 Cipla Limited Suppositoires contenant de la rifaximine
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CN102512358B (zh) * 2011-12-16 2013-04-10 南京农业大学 家畜用利福昔明阴道栓剂及其制备方法
EP2968283A1 (fr) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Rifaximine destinée à être utilisée dans le traitement d'infections vaginales
WO2014140995A2 (fr) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Procédé pour diagnostiquer des infections vaginales
PT3143027T (pt) 2014-05-12 2019-09-20 Alfasigma Spa Nova forma de cristal solvatado de rifaximina, produção, composições e utilização dos mesmos
KR20190026962A (ko) 2014-09-05 2019-03-13 심바이오믹스 세러퓨틱스 엘엘씨 세균질증 치료에 사용하기 위한 세크니다졸
ES2717326T3 (es) 2015-02-26 2019-06-20 Fundacio Inst Dinvestigacio En Ciencies De La Salut Germans Trias I Pujol Composición tópica para el tratamiento de lesiones en mucosas
MX2017011630A (es) 2016-09-08 2018-09-25 Foamix Pharmaceuticals Ltd Composiciones y metodos para tratar rosacea y acne.
US20190008784A1 (en) * 2017-07-07 2019-01-10 Symbiomix Therapeutics, Llc Novel secnidazole soft gelatin capsule formulations and uses thereof
WO2019073321A1 (fr) * 2017-10-10 2019-04-18 Zenvision Pharma Llp Compositions effervescente comprenant de la rifaximine
WO2022090490A1 (fr) * 2020-10-29 2022-05-05 Bausch Health Ireland Limited Formulations liquides de rifaximine destinées à être utilisées dans le traitement de la drépanocytose

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI812936L (fi) * 1980-09-25 1982-03-26 Ciba Geigy Ag Nya 2-aminoimidazoler foerfaranden foer deras framstaellning dessa foereningar innehaollande farmaceutiska preparat och deras anvaendning
ZA816635B (en) * 1980-09-25 1982-09-29 Ciba Geigy Novel 2-aminoimidazoles
IT1190445B (it) * 1985-11-08 1988-02-16 Fatro Spa Composizioni veterinarie a base di agenti antimicrobici e loro impiego
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
DE69011557T2 (de) * 1989-03-31 1995-03-23 Lepetit Spa Verwendung von Purpuromycin zur Behandlung von Vaginalinfektionen.
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
GB9001019D0 (en) * 1990-01-17 1990-03-14 Euro Celtique Sa Pharmaceutical aerosol

Also Published As

Publication number Publication date
KR930012015A (ko) 1993-07-20
JPH05255085A (ja) 1993-10-05
CA2073601C (fr) 1996-07-09
ITBO910476A0 (it) 1991-12-17
EP0547294A1 (fr) 1993-06-23
US6140355A (en) 2000-10-31
ES2081531T3 (es) 1996-03-16
TW217385B (fr) 1993-12-11
IT1253711B (it) 1995-08-23
EP0547294B1 (fr) 1995-11-22
ITBO910476A1 (it) 1993-06-17
KR0149519B1 (ko) 1998-10-15
JP2834951B2 (ja) 1998-12-14
DE69206245T2 (de) 1996-05-02
ATE130510T1 (de) 1995-12-15
MX9204132A (es) 1993-08-01
GR3018205T3 (en) 1996-02-29
DE69206245D1 (de) 1996-01-04
US5314904A (en) 1994-05-24
DK0547294T3 (da) 1995-12-18

Similar Documents

Publication Publication Date Title
CA2073601A1 (fr) Composition pharmaceutique contenant de la rifaximine pour le traitement des infections vaginales
CA2177683A1 (fr) Compositions anti-microbiennes d'humidification des tissus
NZ337246A (en) Pharmaceutical composition comprising amoxycillin and clavulanate
EP0142426A3 (fr) Formulation ophtalmique contenant de la norfloxacine et antibiotiques apparentés
CA2143263A1 (fr) Formulations pharmaceutiques pouvant etre administrees par voie orale
CA2105487A1 (fr) Combinaison de nucleosides antivirale
CA2277824A1 (fr) Formulation destinee a un apport nasal et procede d'utilisation associe
CA2246730A1 (fr) Caramels renfermant un edulcorant
IL136088A0 (en) 6-0-alkyl erythromycin b oxime
DE69631609D1 (en) Tricyclische erythromycinderivate
WO2000026224A3 (fr) Nouveaux antibiotiques macrolide
AU3573793A (en) 3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidine-4-ones pharmaceutical compositions containing the same and the preparation thereof
CA2135346A1 (fr) Melange naturel compose d'alcools aliphatiques primaires superieurs obtenus a partir de la cire d'abeille pour le traitement des ulceres gastriques et duodenaux, qui presente aussi une activite antiinflammatoire
AU6193494A (en) Anti-allergic pharmaceutical composition for ophthalmic topical administration
IL110511A0 (en) Topical pharmaceutical formulation for treating viral infections
AU5294393A (en) Topical pharmaceutical compositions
GB9210096D0 (en) 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives and their preparation
GR3004113T3 (fr)
GB9402351D0 (en) Formulations for the topical delivery of avermectins
CA2114629A1 (fr) Conjugues a recepteurs pour le ciblage d'antibiotiques a des bacteries
ZA89811B (en) B-lactam antibiotics,processes for their preparation and their use as and in medicaments
AU7379587A (en) Pharmaceutical formulation for the treatment of bacterial infections
DZ3039A1 (fr) Doses mensuelles pour le traitement d'infections par streptococcus pneumoniae.
CA2088370A1 (fr) Utilisation d'anticorps monoclonaux
CA2013226A1 (fr) Derives de cephalosporine et procede de preparation

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry